(SD2016-077) Patented Technology: Cas9 polypeptides which target RNA and method of using them are provided
Tech ID: 27089 / UC Case 2016-077-0
Background
Researchers at University of California, San Diego invented and patented a technology that establishes RCas9 as a means to track RNA in living cells in a programmable manner without genetically encoded tags, and may open doors to new treatments for many conditions, from cancer to autism.
Presently, UCSD is offering to license patent rights in the United States (US 11,667,903) and other countries listed below:
Technology Description
RNA-targeting Cas9 enables tracking of endogenous, untagged mRNA, establishing CRISPR/Cas9 as a programmable system to recognize RNA in live cells.
Related Materials
- Nelles DA, Fang MY, O'Connell MR, Xu JL, Markmiller SJ, Doudna JA, Yeo GW. Programmable RNA Tracking in Live Cells with CRISPR/Cas9. Cell. 2016 Apr 7;165(2):488-96. - 04/07/2016
- (VIDEO) How to Target RNA in Live Cells using CRISPR-Cas9, with Dr. Gene Yeo of UC San Diego
Patent Status
| Country | Type | Number | Dated | Case |
| Patent Cooperation Treaty | Published Application | 2017091630 | 06/01/2017 | 2016-077 |
Additional Patent Pending
Contact
- Skip Cynar
- scynar@ucsd.edu
- tel: View Phone Number.
Other Information
Keywords
CRISP-Cas9, gene editing, RNA tracking
